$ALLO Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Allogene Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Allogene Therapeutics, Inc.. Get notifications about new insider transactions in Allogene Therapeutics, Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 11 2021 | ALLO | Allogene Therapeut ... | WITTE OWEN N. | Option Exercise | A | 25.76 | 28,015 | 721,666 | 28,015 | ||
| Jun 11 2021 | ALLO | Allogene Therapeut ... | WITTE OWEN N. | Sell | S | 25.05 | 9,969 | 249,723 | 236,182 | 246.2 K to 236.2 K (-4.05 %) | |
| Jun 11 2021 | ALLO | Allogene Therapeut ... | Kazam Joshua A | Gift | G | 0.00 | 500,000 | 0 | 243,885 | 743.9 K to 243.9 K (-67.21 %) | |
| Jun 11 2021 | ALLO | Allogene Therapeut ... | Kazam Joshua A | Grant | A | 0.00 | 16,498 | 0 | 743,885 | 727.4 K to 743.9 K (+2.27 %) | |
| May 26 2021 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Option Exercise | M | 18.22 | 27,410 | 499,410 | 541,190 | |
| May 26 2021 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | M | 18.22 | 27,410 | 499,410 | 2,312,279 | 2.3 M to 2.3 M (+1.20 %) |
| May 25 2021 | ALLO | Allogene Therapeut ... | Belldegrun Arie | Option Exercise | M | 18.22 | 379,066 | 6,906,583 | 0 | ||
| May 25 2021 | ALLO | Allogene Therapeut ... | Belldegrun Arie | Buy | M | 18.22 | 379,066 | 6,906,583 | 583,034 | 204 K to 583 K (+185.85 %) | |
| Apr 16 2021 | ALLO | Allogene Therapeut ... | Bhavnagri Veer | General Counsel | Option Exercise | M | 2.27 | 10,000 | 22,700 | 142,300 | |
| Apr 16 2021 | ALLO | Allogene Therapeut ... | Bhavnagri Veer | General Counsel | Sell | S | 32.64 | 606 | 19,780 | 421,353 | 422 K to 421.4 K (-0.14 %) |
| Apr 16 2021 | ALLO | Allogene Therapeut ... | Bhavnagri Veer | General Counsel | Sell | S | 32.01 | 9,394 | 300,738 | 421,959 | 431.4 K to 422 K (-2.18 %) |
| Apr 16 2021 | ALLO | Allogene Therapeut ... | Bhavnagri Veer | General Counsel | Buy | M | 2.27 | 10,000 | 22,700 | 431,353 | 421.4 K to 431.4 K (+2.37 %) |
| Mar 30 2021 | ALLO | Allogene Therapeut ... | SCHMIDT ERIC THOMAS | Chief Financial Off ... | Option Exercise | A | 33.78 | 92,365 | 3,120,090 | 92,365 | |
| Mar 30 2021 | ALLO | Allogene Therapeut ... | SCHMIDT ERIC THOMAS | Chief Financial Off ... | Grant | A | 0.00 | 24,866 | 0 | 96,097 | 71.2 K to 96.1 K (+34.91 %) |
| Mar 17 2021 | ALLO | Allogene Therapeut ... | Amado Rafael | EVP of R&D and CMO | Sell | S | 38.05 | 2,798 | 106,471 | 110,035 | 112.8 K to 110 K (-2.48 %) |
| Mar 17 2021 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Sell | S | 38.57 | 20,513 | 791,271 | 2,204,417 | 2.2 M to 2.2 M (-0.92 %) |
| Jan 19 2021 | ALLO | Allogene Therapeut ... | SCHMIDT ERIC THOMAS | Chief Financial Off ... | Sell | S | 33.29 | 400 | 13,314 | 1,152,595 | 1.2 M to 1.2 M (-0.03 %) |
| Jan 19 2021 | ALLO | Allogene Therapeut ... | SCHMIDT ERIC THOMAS | Chief Financial Off ... | Sell | S | 32.40 | 11,053 | 358,151 | 1,152,995 | 1.2 M to 1.2 M (-0.95 %) |
| Jan 19 2021 | ALLO | Allogene Therapeut ... | SCHMIDT ERIC THOMAS | Chief Financial Off ... | Sell | S | 31.69 | 3,547 | 112,393 | 1,164,048 | 1.2 M to 1.2 M (-0.30 %) |
| Jan 19 2021 | ALLO | Allogene Therapeut ... | SCHMIDT ERIC THOMAS | Chief Financial Off ... | Sell | S | 31.10 | 5,149 | 160,129 | 1,167,595 | 1.2 M to 1.2 M (-0.44 %) |
| Jan 19 2021 | ALLO | Allogene Therapeut ... | SCHMIDT ERIC THOMAS | Chief Financial Off ... | Sell | S | 30.60 | 9,851 | 301,481 | 1,172,744 | 1.2 M to 1.2 M (-0.83 %) |
| Dec 18 2020 | ALLO | Allogene Therapeut ... | Bhavnagri Veer | General Counsel | Option Exercise | M | 2.27 | 51,500 | 116,905 | 162,300 | |
| Dec 18 2020 | ALLO | Allogene Therapeut ... | Bhavnagri Veer | General Counsel | Buy | M | 2.27 | 51,500 | 116,905 | 405,402 | 353.9 K to 405.4 K (+14.55 %) |
| Oct 16 2020 | ALLO | Allogene Therapeut ... | SCHMIDT ERIC THOMAS | Chief Financial Off ... | Sell | S | 43.01 | 100 | 4,301 | 1,197,595 | 1.2 M to 1.2 M (-0.01 %) |
| Oct 16 2020 | ALLO | Allogene Therapeut ... | SCHMIDT ERIC THOMAS | Chief Financial Off ... | Sell | S | 42.32 | 2,099 | 88,840 | 1,197,695 | 1.2 M to 1.2 M (-0.17 %) |
| Oct 16 2020 | ALLO | Allogene Therapeut ... | SCHMIDT ERIC THOMAS | Chief Financial Off ... | Sell | S | 41.33 | 3,479 | 143,800 | 1,199,794 | 1.2 M to 1.2 M (-0.29 %) |
| Oct 16 2020 | ALLO | Allogene Therapeut ... | SCHMIDT ERIC THOMAS | Chief Financial Off ... | Sell | S | 40.07 | 4,218 | 169,011 | 1,203,273 | 1.2 M to 1.2 M (-0.35 %) |
| Oct 16 2020 | ALLO | Allogene Therapeut ... | SCHMIDT ERIC THOMAS | Chief Financial Off ... | Sell | S | 39.47 | 5,104 | 201,442 | 1,207,491 | 1.2 M to 1.2 M (-0.42 %) |
| Oct 13 2020 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Option Exercise | M | 2.27 | 11,031 | 25,040 | 579,959 | |
| Oct 13 2020 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Option Exercise | M | 2.27 | 24,233 | 55,009 | 590,990 | |
| Oct 13 2020 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Sell | S | 42.00 | 11,031 | 463,302 | 108,370 | 119.4 K to 108.4 K (-9.24 %) |
| Oct 13 2020 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Buy | M | 2.27 | 11,031 | 25,040 | 119,401 | 108.4 K to 119.4 K (+10.18 %) |
| Oct 13 2020 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Sell | S | 42.00 | 24,233 | 1,017,786 | 108,370 | 132.6 K to 108.4 K (-18.27 %) |
| Oct 13 2020 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Buy | M | 2.27 | 24,233 | 55,009 | 132,603 | 108.4 K to 132.6 K (+22.36 %) |
| Oct 08 2020 | ALLO | Allogene Therapeut ... | Amado Rafael | EVP of R&D and CMO | Sell | S | 39.40 | 16,538 | 651,515 | 111,677 | 128.2 K to 111.7 K (-12.90 %) |
| Oct 08 2020 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Option Exercise | M | 2.27 | 35,264 | 80,049 | 650,487 | |
| Oct 08 2020 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Sell | S | 40.00 | 44,574 | 1,782,960 | 117,680 | 162.3 K to 117.7 K (-27.47 %) |
| Oct 08 2020 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Buy | M | 2.27 | 35,264 | 80,049 | 161,536 | 126.3 K to 161.5 K (+27.93 %) |
| Oct 08 2020 | ALLO | Allogene Therapeut ... | Bhavnagri Veer | General Counsel | Option Exercise | M | 2.27 | 10,000 | 22,700 | 213,800 | |
| Oct 08 2020 | ALLO | Allogene Therapeut ... | Bhavnagri Veer | General Counsel | Sell | S | 40.00 | 10,000 | 400,000 | 353,902 | 363.9 K to 353.9 K (-2.75 %) |
| Oct 08 2020 | ALLO | Allogene Therapeut ... | Bhavnagri Veer | General Counsel | Buy | M | 2.27 | 10,000 | 22,700 | 363,902 | 353.9 K to 363.9 K (+2.83 %) |
| Oct 02 2020 | ALLO | Allogene Therapeut ... | Bhavnagri Veer | General Counsel | Option Exercise | M | 2.27 | 25,000 | 56,750 | 223,800 | |
| Oct 02 2020 | ALLO | Allogene Therapeut ... | Bhavnagri Veer | General Counsel | Sell | S | 37.73 | 800 | 30,180 | 353,902 | 354.7 K to 353.9 K (-0.23 %) |
| Oct 02 2020 | ALLO | Allogene Therapeut ... | Bhavnagri Veer | General Counsel | Sell | S | 37.03 | 7,985 | 295,664 | 354,702 | 362.7 K to 354.7 K (-2.20 %) |
| Oct 02 2020 | ALLO | Allogene Therapeut ... | Bhavnagri Veer | General Counsel | Sell | S | 36.21 | 16,215 | 587,069 | 362,687 | 378.9 K to 362.7 K (-4.28 %) |
| Oct 02 2020 | ALLO | Allogene Therapeut ... | Bhavnagri Veer | General Counsel | Buy | M | 2.27 | 25,000 | 56,750 | 378,902 | 353.9 K to 378.9 K (+7.06 %) |
| Sep 22 2020 | ALLO | Allogene Therapeut ... | SCHMIDT ERIC THOMAS | Chief Financial Off ... | Sell | S | 37.04 | 1,911 | 70,783 | 1,212,595 | 1.2 M to 1.2 M (-0.16 %) |
| Sep 22 2020 | ALLO | Allogene Therapeut ... | SCHMIDT ERIC THOMAS | Chief Financial Off ... | Sell | S | 35.96 | 3,200 | 115,069 | 1,214,506 | 1.2 M to 1.2 M (-0.26 %) |
| Sep 22 2020 | ALLO | Allogene Therapeut ... | SCHMIDT ERIC THOMAS | Chief Financial Off ... | Sell | S | 34.76 | 9,889 | 343,692 | 1,217,706 | 1.2 M to 1.2 M (-0.81 %) |
| Sep 22 2020 | ALLO | Allogene Therapeut ... | SCHMIDT ERIC THOMAS | Chief Financial Off ... | Sell | S | 37.04 | 1,911 | 70,783 | 1,212,595 | 1.2 M to 1.2 M (-0.16 %) |
| Sep 22 2020 | ALLO | Allogene Therapeut ... | SCHMIDT ERIC THOMAS | Chief Financial Off ... | Sell | S | 35.96 | 3,200 | 115,069 | 1,214,506 | 1.2 M to 1.2 M (-0.26 %) |
| Sep 22 2020 | ALLO | Allogene Therapeut ... | SCHMIDT ERIC THOMAS | Chief Financial Off ... | Sell | S | 34.76 | 9,889 | 343,692 | 1,217,706 | 1.2 M to 1.2 M (-0.81 %) |
| Aug 14 2020 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Option Exercise | M | 2.27 | 32,451 | 73,664 | 685,751 | |
| Aug 14 2020 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Buy | M | 2.27 | 32,451 | 73,664 | 126,272 | 93.8 K to 126.3 K (+34.59 %) |
| Aug 10 2020 | ALLO | Allogene Therapeut ... | TPG Group Holdings (SBS) Advis ... | 10% Owner | Sell | S | 37.70 | 7,686 | 289,731 | 18,716,306 | 18.7 M to 18.7 M (-0.04 %) |
| Aug 10 2020 | ALLO | Allogene Therapeut ... | TPG Group Holdings (SBS) Advis ... | 10% Owner | Sell | S | 37.02 | 5,605 | 207,506 | 18,723,992 | 18.7 M to 18.7 M (-0.03 %) |
| Aug 10 2020 | ALLO | Allogene Therapeut ... | TPG Group Holdings (SBS) Advis ... | 10% Owner | Sell | S | 37.33 | 19,554 | 730,002 | 18,729,597 | 18.7 M to 18.7 M (-0.10 %) |
| Aug 10 2020 | ALLO | Allogene Therapeut ... | TPG Group Holdings (SBS) Advis ... | 10% Owner | Sell | S | 38.22 | 4,600 | 175,793 | 18,749,151 | 18.8 M to 18.7 M (-0.02 %) |
| Aug 10 2020 | ALLO | Allogene Therapeut ... | TPG Group Holdings (SBS) Advis ... | 10% Owner | Sell | J | 0.00 | 962,555 | 0 | 18,753,751 | 19.7 M to 18.8 M (-4.88 %) |
| Aug 05 2020 | ALLO | Allogene Therapeut ... | Bhavnagri Veer | General Counsel | Option Exercise | M | 2.27 | 25,000 | 56,750 | 273,800 | |
| Aug 05 2020 | ALLO | Allogene Therapeut ... | Bhavnagri Veer | General Counsel | Sell | S | 37.29 | 16,450 | 613,397 | 353,902 | 370.4 K to 353.9 K (-4.44 %) |
| Aug 05 2020 | ALLO | Allogene Therapeut ... | Bhavnagri Veer | General Counsel | Sell | S | 36.46 | 15,103 | 550,723 | 370,352 | 385.5 K to 370.4 K (-3.92 %) |
| Aug 05 2020 | ALLO | Allogene Therapeut ... | Bhavnagri Veer | General Counsel | Buy | M | 2.27 | 25,000 | 56,750 | 385,455 | 360.5 K to 385.5 K (+6.94 %) |
| Jun 30 2020 | ALLO | Allogene Therapeut ... | TPG Group Holdings (SBS) Advis ... | 10% Owner | Sell | S | 42.21 | 59,747 | 2,522,052 | 19,716,306 | 19.8 M to 19.7 M (-0.30 %) |
| Jun 30 2020 | ALLO | Allogene Therapeut ... | TPG Group Holdings (SBS) Advis ... | 10% Owner | Sell | S | 42.21 | 59,747 | 2,522,052 | 19,716,306 | 19.8 M to 19.7 M (-0.30 %) |
| Jun 30 2020 | ALLO | Allogene Therapeut ... | TPG Group Holdings (SBS) Advis ... | 10% Owner | Sell | S | 43.27 | 24,904 | 1,077,544 | 19,776,053 | 19.8 M to 19.8 M (-0.13 %) |
| Jun 30 2020 | ALLO | Allogene Therapeut ... | TPG Group Holdings (SBS) Advis ... | 10% Owner | Sell | S | 43.27 | 24,904 | 1,077,544 | 19,776,053 | 19.8 M to 19.8 M (-0.13 %) |
| Jun 30 2020 | ALLO | Allogene Therapeut ... | TPG Group Holdings (SBS) Advis ... | 10% Owner | Sell | S | 44.01 | 500 | 22,005 | 19,800,957 | 19.8 M to 19.8 M (0.00 %) |
| Jun 30 2020 | ALLO | Allogene Therapeut ... | TPG Group Holdings (SBS) Advis ... | 10% Owner | Sell | S | 44.01 | 500 | 22,005 | 19,800,957 | 19.8 M to 19.8 M (0.00 %) |
| Jun 25 2020 | ALLO | Allogene Therapeut ... | TPG Group Holdings (SBS) Advis ... | 10% Owner | Sell | S | 44.19 | 72,359 | 3,197,327 | 19,801,457 | 19.9 M to 19.8 M (-0.36 %) |
| Jun 25 2020 | ALLO | Allogene Therapeut ... | TPG Group Holdings (SBS) Advis ... | 10% Owner | Sell | S | 43.93 | 15,269 | 670,714 | 19,873,816 | 19.9 M to 19.9 M (-0.08 %) |
| Jun 25 2020 | ALLO | Allogene Therapeut ... | TPG Group Holdings (SBS) Advis ... | 10% Owner | Sell | S | 44.31 | 22,213 | 984,236 | 19,889,085 | 19.9 M to 19.9 M (-0.11 %) |
| Jun 25 2020 | ALLO | Allogene Therapeut ... | TPG Group Holdings (SBS) Advis ... | 10% Owner | Sell | S | 43.91 | 110,012 | 4,830,374 | 19,911,298 | 20 M to 19.9 M (-0.55 %) |
| Jun 22 2020 | ALLO | Allogene Therapeut ... | TPG Group Holdings (SBS) Advis ... | 10% Owner | Sell | S | 43.16 | 42,855 | 1,849,828 | 20,021,310 | 20.1 M to 20 M (-0.21 %) |
| Jun 22 2020 | ALLO | Allogene Therapeut ... | TPG Group Holdings (SBS) Advis ... | 10% Owner | Sell | S | 42.72 | 129,570 | 5,534,894 | 20,064,165 | 20.2 M to 20.1 M (-0.64 %) |
| Jun 22 2020 | ALLO | Allogene Therapeut ... | TPG Group Holdings (SBS) Advis ... | 10% Owner | Sell | S | 42.04 | 47,767 | 2,008,306 | 20,193,735 | 20.2 M to 20.2 M (-0.24 %) |
| Jun 22 2020 | ALLO | Allogene Therapeut ... | TPG Group Holdings (SBS) Advis ... | 10% Owner | Sell | S | 42.14 | 94,600 | 3,986,595 | 20,241,502 | 20.3 M to 20.2 M (-0.47 %) |
| Jun 17 2020 | ALLO | Allogene Therapeut ... | TPG Group Holdings (SBS) Advis ... | 10% Owner | Sell | S | 42.18 | 87,319 | 3,683,482 | 20,336,102 | 20.4 M to 20.3 M (-0.43 %) |
| Jun 17 2020 | ALLO | Allogene Therapeut ... | TPG Group Holdings (SBS) Advis ... | 10% Owner | Sell | S | 42.20 | 174,511 | 7,364,678 | 20,423,421 | 20.6 M to 20.4 M (-0.85 %) |
| Jun 17 2020 | ALLO | Allogene Therapeut ... | TPG Group Holdings (SBS) Advis ... | 10% Owner | Sell | S | 42.14 | 129,154 | 5,442,885 | 20,597,932 | 20.7 M to 20.6 M (-0.62 %) |
| Jun 09 2020 | ALLO | Allogene Therapeut ... | WITTE OWEN N. | Grant | A | 0.00 | 9,969 | 0 | 246,151 | 236.2 K to 246.2 K (+4.22 %) | |
| Jun 09 2020 | ALLO | Allogene Therapeut ... | MESSEMER DEBORAH M. | Option Exercise | A | 42.63 | 16,640 | 709,363 | 16,640 | ||
| Jun 05 2020 | ALLO | Allogene Therapeut ... | TPG Group Holdings (SBS) Advis ... | 10% Owner | Sell | S | 47.11 | 1,818 | 85,638 | 20,727,086 | 20.7 M to 20.7 M (-0.01 %) |
| Jun 05 2020 | ALLO | Allogene Therapeut ... | TPG Group Holdings (SBS) Advis ... | 10% Owner | Sell | S | 47.13 | 274,080 | 12,916,815 | 20,728,904 | 21 M to 20.7 M (-1.30 %) |
| Jun 05 2020 | ALLO | Allogene Therapeut ... | TPG Group Holdings (SBS) Advis ... | 10% Owner | Sell | S | 47.75 | 213,322 | 10,185,699 | 21,002,984 | 21.2 M to 21 M (-1.01 %) |
| Jun 04 2020 | ALLO | Allogene Therapeut ... | Belldegrun Arie | Buy | P | 47.00 | 106,382 | 4,999,954 | 1,798,163 | 1.7 M to 1.8 M (+6.29 %) | |
| Jun 04 2020 | ALLO | Allogene Therapeut ... | Belldegrun Arie | Buy | P | 47.00 | 40,000 | 1,880,000 | 40,000 | 0 to 40 K | |
| Apr 28 2020 | ALLO | Allogene Therapeut ... | Kazam Joshua A | Buy | J | 0.00 | 8,039 | 0 | 1,023,336 | 1 M to 1 M (+0.79 %) | |
| Apr 28 2020 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Gift | G | 0.00 | 428,022 | 0 | 650,266 | 222.2 K to 650.3 K (+192.59 %) |
| Apr 28 2020 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Gift | G | 0.00 | 428,022 | 0 | 650,266 | 222.2 K to 650.3 K (+192.59 %) |
| Apr 28 2020 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 9,187 | 0 | 2,224,101 | 2.2 M to 2.2 M (+0.41 %) |
| Apr 28 2020 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 9,198 | 0 | 1,201,108 | 1.2 M to 1.2 M (+0.77 %) |
| Mar 20 2020 | ALLO | Allogene Therapeut ... | Belldegrun Arie | Option Exercise | A | 18.22 | 379,066 | 6,906,583 | 379,066 | ||
| Mar 20 2020 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Option Exercise | A | 18.22 | 568,600 | 10,359,892 | 568,600 | |
| Mar 20 2020 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Option Exercise | A | 18.22 | 109,600 | 1,996,912 | 109,600 | |
| Mar 20 2020 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Grant | A | 0.00 | 30,800 | 0 | 93,821 | 63 K to 93.8 K (+48.87 %) |
| Mar 20 2020 | ALLO | Allogene Therapeut ... | Amado Rafael | EVP of R&D and CMO | Option Exercise | A | 18.22 | 109,600 | 1,996,912 | 109,600 | |
| Mar 20 2020 | ALLO | Allogene Therapeut ... | Amado Rafael | EVP of R&D and CMO | Grant | A | 0.00 | 30,800 | 0 | 135,962 | 105.2 K to 136 K (+29.29 %) |
| Mar 20 2020 | ALLO | Allogene Therapeut ... | SCHMIDT ERIC THOMAS | Chief Financial Off ... | Option Exercise | A | 18.22 | 109,600 | 1,996,912 | 109,600 | |
| Mar 20 2020 | ALLO | Allogene Therapeut ... | SCHMIDT ERIC THOMAS | Chief Financial Off ... | Grant | A | 0.00 | 30,800 | 0 | 78,706 | 47.9 K to 78.7 K (+64.29 %) |
| Mar 18 2020 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Sell | S | 19.19 | 3,750 | 71,980 | 63,021 | 66.8 K to 63 K (-5.62 %) |
| Mar 18 2020 | ALLO | Allogene Therapeut ... | SCHMIDT ERIC THOMAS | Chief Financial Off ... | Sell | S | 20.25 | 300 | 6,075 | 47,906 | 48.2 K to 47.9 K (-0.62 %) |
| Mar 18 2020 | ALLO | Allogene Therapeut ... | SCHMIDT ERIC THOMAS | Chief Financial Off ... | Sell | S | 19.70 | 5,150 | 101,433 | 47,257 | 52.4 K to 47.3 K (-9.83 %) |
| Mar 18 2020 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Sell | S | 20.06 | 1,625 | 32,603 | 2,214,914 | 2.2 M to 2.2 M (-0.07 %) |
| Mar 18 2020 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Sell | S | 19.24 | 18,710 | 360,012 | 2,215,426 | 2.2 M to 2.2 M (-0.84 %) |
| Mar 11 2020 | ALLO | Allogene Therapeut ... | Kazam Joshua A | Buy | J | 0.00 | 8,217 | 0 | 1,015,297 | 1 M to 1 M (+0.82 %) | |
| Mar 11 2020 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 9,391 | 0 | 2,234,136 | 2.2 M to 2.2 M (+0.42 %) |
| Mar 11 2020 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 9,402 | 0 | 1,191,910 | 1.2 M to 1.2 M (+0.80 %) |
| Feb 24 2020 | ALLO | Allogene Therapeut ... | SCHMIDT ERIC THOMAS | Chief Financial Off ... | Sell | J | 25.30 | 237,155 | 6,000,022 | 1,227,595 | 1.5 M to 1.2 M (-16.19 %) |
| Nov 21 2019 | ALLO | Allogene Therapeut ... | Kazam Joshua A | Gift | G | 0.00 | 446,623 | 0 | 1,007,080 | 1.5 M to 1 M (-30.72 %) | |
| Nov 21 2019 | ALLO | Allogene Therapeut ... | Kazam Joshua A | Buy | J | 0.00 | 8,217 | 0 | 1,453,703 | 1.4 M to 1.5 M (+0.57 %) | |
| Nov 21 2019 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 9,391 | 0 | 2,224,745 | 2.2 M to 2.2 M (+0.42 %) |
| Nov 21 2019 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 9,402 | 0 | 1,182,508 | 1.2 M to 1.2 M (+0.80 %) |
| Oct 29 2019 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 9,391 | 0 | 2,215,354 | 2.2 M to 2.2 M (+0.43 %) |
| Oct 29 2019 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 9,402 | 0 | 1,173,106 | 1.2 M to 1.2 M (+0.81 %) |
| Oct 29 2019 | ALLO | Allogene Therapeut ... | Kazam Joshua A | Buy | J | 0.00 | 8,217 | 0 | 1,445,486 | 1.4 M to 1.4 M (+0.57 %) | |
| Sep 25 2019 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 9,391 | 0 | 2,205,963 | 2.2 M to 2.2 M (+0.43 %) |
| Sep 25 2019 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 9,402 | 0 | 1,163,704 | 1.2 M to 1.2 M (+0.81 %) |
| Sep 25 2019 | ALLO | Allogene Therapeut ... | Kazam Joshua A | Buy | J | 0.00 | 8,217 | 0 | 1,437,269 | 1.4 M to 1.4 M (+0.57 %) | |
| Sep 18 2019 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Option Exercise | M | 2.27 | 21,067 | 47,822 | 718,202 | |
| Sep 18 2019 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Option Exercise | M | 2.27 | 22,503 | 51,082 | 739,269 | |
| Sep 18 2019 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Option Exercise | M | 2.27 | 5,257 | 11,933 | 761,772 | |
| Sep 18 2019 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Sell | S | 32.13 | 21,067 | 676,872 | 66,067 | 87.1 K to 66.1 K (-24.18 %) |
| Sep 18 2019 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Buy | M | 2.27 | 21,067 | 47,822 | 87,134 | 66.1 K to 87.1 K (+31.89 %) |
| Sep 18 2019 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Sell | S | 32.11 | 22,503 | 722,560 | 66,067 | 88.6 K to 66.1 K (-25.41 %) |
| Sep 18 2019 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Buy | M | 2.27 | 22,503 | 51,082 | 88,570 | 66.1 K to 88.6 K (+34.06 %) |
| Sep 18 2019 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Sell | S | 32.00 | 5,257 | 168,234 | 66,067 | 71.3 K to 66.1 K (-7.37 %) |
| Sep 18 2019 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Buy | M | 2.27 | 5,257 | 11,933 | 71,324 | 66.1 K to 71.3 K (+7.96 %) |
| Sep 09 2019 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 9,391 | 0 | 2,195,469 | 2.2 M to 2.2 M (+0.43 %) |
| Sep 09 2019 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 9,402 | 0 | 1,154,302 | 1.1 M to 1.2 M (+0.82 %) |
| Sep 09 2019 | ALLO | Allogene Therapeut ... | Kazam Joshua A | Buy | J | 0.00 | 8,217 | 0 | 1,429,052 | 1.4 M to 1.4 M (+0.58 %) | |
| Sep 05 2019 | ALLO | Allogene Therapeut ... | Amado Rafael | EVP of R&D and CMO | Option Exercise | A | 26.15 | 160,630 | 4,200,475 | 160,630 | |
| Sep 05 2019 | ALLO | Allogene Therapeut ... | Amado Rafael | EVP of R&D and CMO | Grant | A | 0.00 | 105,162 | 0 | 105,162 | 0 to 105.2 K |
| Sep 05 2019 | ALLO | Allogene Therapeut ... | Amado Rafael | EVP of R&D and CMO | Option Exercise | A | 26.15 | 160,630 | 4,200,475 | 160,630 | |
| Sep 05 2019 | ALLO | Allogene Therapeut ... | Amado Rafael | EVP of R&D and CMO | Grant | A | 0.00 | 105,162 | 0 | 105,162 | 0 to 105.2 K |
| Jul 30 2019 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Option Exercise | M | 2.27 | 11,819 | 26,829 | 767,029 | |
| Jul 30 2019 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Option Exercise | M | 2.27 | 23,815 | 54,060 | 778,848 | |
| Jul 30 2019 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Option Exercise | M | 2.27 | 13,193 | 29,948 | 802,663 | |
| Jul 30 2019 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Sell | S | 29.85 | 11,819 | 352,738 | 65,373 | 77.2 K to 65.4 K (-15.31 %) |
| Jul 30 2019 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Buy | M | 2.27 | 11,819 | 26,829 | 77,192 | 65.4 K to 77.2 K (+18.08 %) |
| Jul 30 2019 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Sell | S | 29.39 | 23,815 | 699,870 | 65,373 | 89.2 K to 65.4 K (-26.70 %) |
| Jul 30 2019 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Buy | M | 2.27 | 23,815 | 54,060 | 89,188 | 65.4 K to 89.2 K (+36.43 %) |
| Jul 30 2019 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Sell | S | 29.18 | 13,193 | 384,994 | 65,373 | 78.6 K to 65.4 K (-16.79 %) |
| Jul 30 2019 | ALLO | Allogene Therapeut ... | MOORE ALISON | Chief Technical Off ... | Buy | M | 2.27 | 13,193 | 29,948 | 78,566 | 65.4 K to 78.6 K (+20.18 %) |
| Jul 22 2019 | ALLO | Allogene Therapeut ... | Kazam Joshua A | Director | Buy | J | 0.00 | 8,217 | 0 | 1,420,835 | 1.4 M to 1.4 M (+0.58 %) |
| Jul 22 2019 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 9,391 | 0 | 2,186,078 | 2.2 M to 2.2 M (+0.43 %) |
| Jul 22 2019 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 9,402 | 0 | 1,144,900 | 1.1 M to 1.1 M (+0.83 %) |
| Jul 12 2019 | ALLO | Allogene Therapeut ... | Kazam Joshua A | Director | Buy | J | 0.00 | 5,590 | 0 | 1,412,618 | 1.4 M to 1.4 M (+0.40 %) |
| Jul 12 2019 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 6,388 | 0 | 2,176,687 | 2.2 M to 2.2 M (+0.29 %) |
| Jul 12 2019 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 10,154 | 0 | 1,135,498 | 1.1 M to 1.1 M (+0.90 %) |